Results 71 to 80 of about 27,659 (185)

The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays

Platelets, 2017
Patients on P2Y12 inhibitors may still develop thrombosis or bleeding complications. Tailored antiplatelet therapy, based on platelet reactivity testing, might reduce these complications.
Tesse C. Leunissen, Peter Paul Wisman, Thijs C. van Holten, Philip G. de Groot, Suzanne J. Korporaal, Arnold C. Koekman, Frans L. Moll, Martin Teraa, Marianne C. Verhaar, Gert Jan de Borst, Rolf T. Urbanus, Mark Roest   +11 more
doaj   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Loss of P2Y12 Has Behavioral Effects in the Adult Mouse

, 2021
While microglia have been established as critical mediators of synaptic plasticity, the molecular signals underlying this process are still being uncovered.
Ania K. Majewska, Allison J. Murphy, Brandon T. Sanders, Cassandra E. Lamantia, Rebecca L. Lowery, Monique S. Mendes, Brendan S. Whitelaw   +6 more
core   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Diabetes‐Induced Dysregulation of Purinergic Signaling in the Bladder Mucosa: Accelerated ATP Hydrolysis and Impaired Adenosine Uptake Promote Underactive Bladder Phenotype

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objective To explore molecular mechanisms underlying excessive extracellular adenosine (ADO) accumulation in the bladder lamina propria (LP) of mice with type 2 diabetes (T2D) induced by a high‐fat, high‐sucrose diet (HFHSD), conceivably leading to bladder underactivity.
Mahsa Borhani Peikani, Brian A. Perrino, Violeta N. Mutafova‐Yambolieva   +2 more
wiley   +1 more source

P2Y12 inhibitors for acute coronary syndromes: current perspectives

, 2015
James J Nawarskas,1 Cheyenne Newsome,2 Joe R Anderson,1 Bina Ahmed3 1Department of Pharmacy Practice and Pharmacy Administration, The University of New Mexico College of Pharmacy, 2Department of Pharmacy, The University of New Mexico Hospitals ...
Newsome C, Ahmed B, Anderson JR, Nawarskas JJ   +3 more
core  

Inhibiting the P2Y12 Receptor in Megakaryocytes and Platelets Suppresses Interferon-Associated Responses

JACC: Basic to Translational Science
Summary: The authors investigated the impact of antiplatelet therapy on the megakaryocyte (MK) and platelet transcriptome. RNA-sequencing was performed on MKs treated with aspirin or P2Y12 inhibitor, platelets from healthy volunteers receiving aspirin or
Marcin A. Sowa, PhD, Haoyu Sun, PhD, Tricia T. Wang, BA, Vitor W. Virginio, PhD, Florencia Schlamp, PhD, Hanane El Bannoudi, PhD, MacIntosh Cornwell, PhD, Hannah Bash, BA, Peter M. Izmirly, MD, H. Michael Belmont, MD, Kelly V. Ruggles, PhD, Jill P. Buyon, MD, Deepak Voora, MD, Tessa J. Barrett, PhD, Jeffrey S. Berger, MD   +14 more
doaj   +1 more source

Safety of Dual‐Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Although recommended in the guidelines, the safety of chronic P2Y12 inhibitor therapy in patients with chronic kidney disease (CKD) after an acute myocardial infarction (MI) is not well studied. Methods and Results The TRANSLATE‐ACS (Treatment
Jennifer A. Rymer, Lisa A. Kaltenbach, Jacob A. Doll, John C. Messenger, Eric D. Peterson, Tracy Y. Wang   +5 more
doaj   +1 more source

Platelet membrane receptor P2Y12 H1/H2 polymorphisms is highly associated with cerebral infarction: a case-control study

, 2018
Shu-Jun Lu, Xiao-Sheng Zhou, Qi Zheng, Hong-Liang Chen, Yan-Lei Geng Department of Neurology, Binzhou Medical University Hospital, Binzhou, People’s Republic of China Objectives: This study aimed to determine the relationship between the ...
Lu SJ, Zheng Q, Zhou XS, Chen HL, Geng YL   +4 more
core  

Bioactive Natural Products in Cardiovascular Disease: Focus on Thrombotic Events

Phytotherapy Research, EarlyView.
An overview of the role of natural products (NP) in cardiovascular disease prevention, highlighting key mechanisms of action: including antiplatelet, antithrombotic, anti‐inflammatory, and antioxidant effects. Additionally, it illustrates the integration of diet–drug interactions, nutritional epigenetics, and the role of artificial intelligence in ...
Maria Nektaria Magkoulia, Despoina Pantazi   +1 more
wiley   +1 more source